IceCure's ProSense Finds Its Commercial Bite: Revenue Up 45% as CHOICE Study Gains Traction

IceCure Medical (NASDAQ: ICCM) has reached a genuine inflection point. The company's H1 2026 results, reported on August 12, show revenue growth of approximately 45% year-over-year to $1.8 million, driven by both ProSense systems and disposable probes. But the more meaningful story is the strategic convergence management highlighted: “As more physicians adopt ProSense, they generate additional real-world evidence creating a self-reinforcing cycle that we believe will continue to strengthen over time.” — Eyal Shamir, CEO · 2026-08-12 This is no longer a pure clinical-stage narrative; the company is actively converting its clinical momentum into commercial traction.

Commercial Momentum Turns Real

The revenue expansion is accompanied by a 70% growth in the active U.S. commercial installed base, now above 30 sites. CEO Eyal Shamir emphasized that physician adoption is deepening, not just broadening: “We are seeing more utilization of our single-use probe, reflecting physicians incorporating ProSense into routine clinical practice.” — Operator · 2026-05-12 The disposable probe sales growth is particularly encouraging, as it signals recurring patient treatment rather than one-time system placements. CFO Meir Peleg added color on the mix: “Revenue for the first half of 26 increased approximately 45% year over year to $1.8 million compared to €1.25 million in the same period last year.” — Meir Peleg, CFO · 2026-08-12 This trajectory, combined with a strengthened balance sheet (approximately $12 million in cash), positions the company to fund its commercial and clinical expansion without near-term distress.

CHOICE Study: A Commercial Engine, Not Just a Trial

The CHOICE post-market study is the centerpiece of IceCure's strategy to marry clinical evidence with adoption. Management was explicit that this is not a standard clinical trial: “Unlike traditional pre-market clinical study, the CHOICE trial is a post market study is not separate from our commercialization strategy. Rather it is an extension of it.” — Eyal Shamir, CEO · 2026-08-12 Participating sites purchase disposable probes as part of routine care while contributing real-world data. Already, more than 10 sites are in various stages of contracting and IRB approval, with the first two fully signed and expecting first patient enrollment within 3–4 weeks. As CEO Eyal Shamir noted: “We have in process more than 10... We expect the first patients in the next 3 to 4 weeks.” — Eyal Shamir, CEO · 2026-08-12 This approach not only generates clinical evidence but also converts investigators into commercial adoption, directly expanding the installed base.

Reimbursement: The Next Catalyst

The reimbursement pathway remains a critical near-term driver. On the call, management confirmed they are progressing with the CPT1 code submission to the AMA, with the public agenda for September already listing breast cryoablation. This echoes earlier guidance: “CPT1 is part of establishing a standard of care in the U.S. ... we believe that our next coming inflection point will be early 2028 after we get the CPT1.” — Eyal Shamir, Unknown (likely Executive) · 2026-03-17 The company is also actively pursuing reimbursement initiatives beyond Medicare, including Medicare Advantage, and the transitional pass-through coding is helping sites cover facility costs today. If the CPT1 code is granted, it could trigger exponential growth in procedure volumes, given the current low penetration.

Financial Position and Outlook

With the financing completed in Q2, IceCure ended H1 with about $12 million in cash, enough to execute its near-term objectives. Management refrained from giving formal guidance but noted seasonality: “Normally Q3 is traditionally lower... and Q4 is traditionally our strongest quarter.” — Meir Peleg, CFO · 2026-08-12 Given the H1 momentum and the ongoing site ramp-up, a stronger second half looks plausible. The fundamental story is straightforward: a small-cap with a validated product, clear clinical differentiation, and a commercial engine that is just starting to turn.

<b>"Commercial adoption is supporting clinical evidence and clinical evidence is bolstering physician confidence. Growing physician confidence is expanding commercial adoption. We believe this creates a powerful and sustainable foundation for our long term goals."</b>

Why It Matters

For a company with a market cap under $20 million, this inflection is not merely incremental. The convergence of revenue growth, installed-base expansion, and the CHOICE study's dual purpose represents a strategic pivot from a development-stage company to a commercial one. The market is watching for patient enrollment milestones and CPT1 progress, but the underlying financial and operational metrics are already showing a company entering a new phase. Investors who have followed IceCure know this is a long-term story, but the first-half results provide tangible evidence that the thesis is playing out.